← Back to Publications

Peer-reviewed research contributions

This list was last updated on 2026-06-19.

1. Tian Y, Tang M, Qiao M, …, Nabavi N, et al. (2026). Corrigendum to “STAT3-driven EMT in cancer metastasis and chemoresistance: A review” [Int. J. Biol. Macromol. 357 (2026): 151403]. Int J Biol Macromol, 152938. PubMed
2. Entezari M, Ghanbarirad M, Taheriazam A, …, Nabavi N, et al. (2026). Corrigendum to “Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling” [Biomed. Pharmacother. 150 (2022) 112963]. Biomed Pharmacother, 198, 119309. PubMed
3. Hashemi M, Zandieh MA, Talebi Y, …, Nabavi N, et al. (2026). Retraction notice to “Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies” [Biomedicine & Pharmacotherapy 160 (2023) 114392]. Biomed Pharmacother, 198, 119216. PubMed
4. Tian Y, Tang M, Qiao M, …, Nabavi N, et al. (2026). STAT3-driven EMT in cancer metastasis and chemoresistance: A review. Int J Biol Macromol, 357, 151403. PubMed
5. Yan Y, Liu S, Wen J, …, Nabavi N, et al. (2025). Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications. Mol Cancer, 24(1), 251. PubMed
6. Jiang Y, Zhou Y, Tian Y, …, Nabavi N, et al. (2025). Conductive polymers in smart wound healing: From bioelectric stimulation to regenerative therapies. Mater Today Bio, 34, 102114. PubMed
7. Luo W, Shi Q, Han M, …, Nabavi N, et al. (2025). TGF-β-driven EMT in cancer progression and drug resistance. Cytokine Growth Factor Rev, 85, 11-25. PubMed
8. Hashemi M, Gholamrezaie H, Ziyaei F, …, Nabavi N, et al. (2025). Role of lncRNA PVT1 in the progression of urological cancers: Novel insights into signaling pathways and clinical opportunities. Cell Signal, 131, 111736. PubMed
9. Kahkesh S, Hedayati N, Rahimzadeh P, …, Nabavi N, et al. (2025). The function of circular RNAs in regulating Wnt/β-catenin signaling: An innovative therapeutic strategy for breast and gynecological cancers. Pathol Res Pract, 270, 155944. PubMed
10. Hushmandi K, Imani Fooladi AA, Reiter RJ, …, Nabavi N, et al. (2025). Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines. Exp Hematol Oncol, 14(1), 75. PubMed
11. Zhang M, Liu C, Tu J, …, Nabavi N, et al. (2025). Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer, 24(1), 136. PubMed
12. Miri H, Rahimzadeh P, Hashemi M, …, Nabavi N, et al. (2025). Harnessing immunotherapy for hepatocellular carcinoma: Principles and emerging promises. Pathol Res Pract, 269, 155928. PubMed
13. Alaei E, Hashemi F, Farahani N, …, Nabavi N, et al. (2025). Peptides in breast cancer therapy: From mechanisms to emerging drug delivery and immunotherapy strategies. Pathol Res Pract, 269, 155946. PubMed
14. Hashemi M, Fard AA, Pakshad B, …, Nabavi N, et al. (2025). Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications. Noncoding RNA Res, 11, 1-21. PubMed
15. Hushmandi K, Alimohammadi M, Heiat M, …, Nabavi N, et al. (2025). Targeting Wnt signaling in cancer drug resistance: Insights from pre-clinical and clinical research. Pathol Res Pract, 267, 155837. PubMed
16. Doodmani SM, Safari MH, Akbari M, …, Nabavi N, et al. (2025). Metastasis and chemoresistance in breast cancer: Crucial function of ZEB1/2 proteins. Pathol Res Pract, 267, 155838. PubMed
17. Hashemi M, Khosroshahi EM, Daneii P, …, Nabavi N, et al. (2025). Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response. Noncoding RNA Res, 10, 98-115. PubMed
18. Hashemi M, Mohandesi Khosroshahi E, Asadi S, …, Nabavi N, et al. (2025). Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer. Noncoding RNA Res, 10, 1-15. PubMed
19. Farahani N, Alimohammadi M, Raei M, …, Nabavi N, et al. (2024). Exploring the dual role of endoplasmic reticulum stress in urological cancers: Implications for tumor progression and cell death interactions. J Cell Commun Signal, 18(4), e12054. PubMed
20. Hashemi M, Rezaei M, Rezaeiaghdam H, …, Nabavi N, et al. (2024). Highlighting function of Wnt signalling in urological cancers: Molecular interactions, therapeutic strategies, and (nano)strategies. Transl Oncol, 50, 102145. PubMed
21. Hushmandi K, Klionsky DJ, Aref AR, …, Nabavi N, et al. (2024). Ferroptosis contributes to the progression of female-specific neoplasms, from breast cancer to gynecological malignancies in a manner regulated by non-coding RNAs: Mechanistic implications. Noncoding RNA Res, 9(4), 1159-1177. PubMed
22. Hushmandi K, Einollahi B, Aow R, …, Nabavi N, et al. (2024). Investigating the interplay between mitophagy and diabetic neuropathy: Uncovering the hidden secrets of the disease pathology. Pharmacol Res, 208, 107394. PubMed
23. Hedayati N, Mafi A, Farahani A, …, Nabavi N, et al. (2024). The importance of the circRNA/Wnt axis in gliomas: Biological functions and clinical opportunities. Pathol Res Pract, 261, 155510. PubMed
24. Hedayati N, Safaei Naeini M, Ale Sahebfosoul MM, …, Nabavi N, et al. (2024). MicroRNA dysregulation and its impact on apoptosis-related signaling pathways in myelodysplastic syndrome. Pathol Res Pract, 261, 155478. PubMed
25. Mafi A, Hedayati N, Milasi YE, …, Nabavi N, et al. (2024). The function and mechanism of circRNAs in 5-fluorouracil resistance in tumors: Biological mechanisms and future potential. Pathol Res Pract, 260, 155457. PubMed
26. Shakeri M, Aminian A, Mokhtari K, …, Nabavi N, et al. (2024). Unraveling the molecular landscape of osteoarthritis: A comprehensive review focused on the role of non-coding RNAs. Pathol Res Pract, 260, 155446. PubMed
27. Mafi A, Khoshnazar SM, Shahpar A, …, Nabavi N, et al. (2024). Mechanistic insights into circRNA-mediated regulation of PI3K signaling pathway in glioma progression. Pathol Res Pract, 260, 155442. PubMed
28. Alimohammadi M, Rahimzadeh P, Khorrami R, …, Nabavi N, et al. (2024). A comprehensive review of the PTEN/PI3K/Akt axis in multiple myeloma: From molecular interactions to potential therapeutic targets. Pathol Res Pract, 260, 155401. PubMed
29. Hushmandi K, Saadat SH, Mirilavasani S, …, Nabavi N, et al. (2024). The multifaceted role of SOX2 in breast and lung cancer dynamics. Pathol Res Pract, 260, 155386. PubMed
30. Hashemi M, Khosroshahi EM, Chegini MK, …, Nabavi N, et al. (2024). Mechanistic insights into cisplatin response in breast tumors: Molecular determinants and drug/nanotechnology-based therapeutic opportunities. Mutat Res Rev Mutat Res, 794, 108513. PubMed
31. Hushmandi K, Saadat SH, Raei M, …, Nabavi N, et al. (2024). The science of exosomes: Understanding their formation, capture, and role in cellular communication. Pathol Res Pract, 259, 155388. PubMed
32. Hushmandi K, Saadat SH, Raei M, …, Nabavi N, et al. (2024). Implications of c-Myc in the pathogenesis and treatment efficacy of urological cancers. Pathol Res Pract, 259, 155381. PubMed
33. Samaei SS, Daryab M, Gholami S, …, Nabavi N, et al. (2024). Multifunctional and stimuli-responsive liposomes in hepatocellular carcinoma diagnosis and therapy. Transl Oncol, 45, 101975. PubMed
34. Hushmandi K, Einollahi B, Saadat SH, …, Nabavi N, et al. (2024). Amino acid transporters within the solute carrier superfamily: Underappreciated proteins and novel opportunities for cancer therapy. Mol Metab, 84, 101952. PubMed
35. Hashem M, Mohandesi Khosroshahi E, Aliahmady M, …, Nabavi N, et al. (2024). Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism. Noncoding RNA Res, 9(2), 560-582. PubMed
36. Rezaee A, Rahmanian P, Nemati A, …, Nabavi N, et al. (2024). NF-ĸB axis in diabetic neuropathy, cardiomyopathy and nephropathy: A roadmap from molecular intervention to therapeutic strategies. Heliyon, 10(9), e29871. PubMed
37. Ashrafizadeh M, Dai J, Torabian P, …, Nabavi N, et al. (2024). Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance. Cell Mol Life Sci, 81(1), 214. PubMed
38. Hashemi M, Daneii P, Asadalizadeh M, …, Nabavi N, et al. (2024). Epigenetic regulation of hepatocellular carcinoma progression: MicroRNAs as therapeutic, diagnostic and prognostic factors. Int J Biochem Cell Biol, 170, 106566. PubMed
39. Ebrahimi N, Manavi MS, Faghihkhorasani F, …, Nabavi N, et al. (2024). Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response. Cancer Metastasis Rev, 43(1), 457-479. PubMed
40. Hashemi M, Esbati N, Rashidi M, …, Nabavi N, et al. (2024). Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer. Transl Oncol, 40, 101846. PubMed
41. Baniasadi M, Talebi S, Mokhtari K, …, Nabavi N, et al. (2024). Role of non-coding RNAs in osteoporosis. Pathol Res Pract, 253, 155036. PubMed
42. Karimi B, Mokhtari K, Rozbahani H, …, Nabavi N, et al. (2024). Pathological roles of miRNAs and pseudogene-derived lncRNAs in human cancers, and their comparison as prognosis/diagnosis biomarkers. Pathol Res Pract, 253, 155014. PubMed
43. Hashemi M, Nazdari N, Gholamiyan G, …, Nabavi N, et al. (2024). EZH2 as a potential therapeutic target for gastrointestinal cancers. Pathol Res Pract, 253, 154988. PubMed
44. Yenki P, Bhasin S, Liu L, …, Nabavi N, et al. (2023). Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells. Endocr Relat Cancer, 30(12). PubMed
45. Tehrany PM, Rahmanian P, Rezaee A, …, Nabavi N, et al. (2023). Multifunctional and theranostic hydrogels for wound healing acceleration: An emphasis on diabetic-related chronic wounds. Environ Res, 238(Pt 1), 117087. PubMed
46. Sadeghi MS, Sangrizeh FH, Jahani N, …, Nabavi N, et al. (2023). Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development. Environ Res, 237(Pt 2), 117027. PubMed
47. Hashemi M, Khosroshahi EM, Chegini MK, …, Nabavi N, et al. (2023). miRNAs and exosomal miRNAs in lung cancer: New emerging players in tumor progression and therapy response. Pathol Res Pract, 251, 154906. PubMed
48. Sadrkhanloo M, Paskeh MDA, Hashemi M, …, Nabavi N, et al. (2023). New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis. Pathol Res Pract, 251, 154902. PubMed
49. Hashemi M, Razzazan M, Bagheri M, …, Nabavi N, et al. (2023). Versatile function of AMPK signaling in osteosarcoma: An old player with new emerging carcinogenic functions. Pathol Res Pract, 251, 154849. PubMed
50. Zandieh MA, Farahani MH, Daryab M, …, Nabavi N, et al. (2023). Stimuli-responsive (nano)architectures for phytochemical delivery in cancer therapy. Biomed Pharmacother, 166, 115283. PubMed
51. Rezaei S, Nikpanjeh N, Rezaee A, …, Nabavi N, et al. (2023). PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation. Eur J Pharmacol, 955, 175909. PubMed
52. Hashemi M, Abbaszadeh S, Rashidi M, …, Nabavi N, et al. (2023). STAT3 as a newly emerging target in colorectal cancer therapy: Tumorigenesis, therapy response, and pharmacological/nanoplatform strategies. Environ Res, 233, 116458. PubMed
53. Rezaee A, Tehrany PM, Tirabadi FJ, …, Nabavi N, et al. (2023). Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs. Biomed Pharmacother, 165, 115187. PubMed
54. Hashemi M, Gholami S, Raesi R, …, Nabavi N, et al. (2023). Biological and therapeutic viewpoints towards role of miR-218 in human cancers: Revisiting molecular interactions and future clinical translations. Cell Signal, 109, 110786. PubMed
55. Al-Rashidi RR, Noraldeen SAM, Kareem AK, …, Nabavi N, et al. (2023). Malignant function of nuclear factor-kappaB axis in prostate cancer: Molecular interactions and regulation by non-coding RNAs. Pharmacol Res, 194, 106775. PubMed
56. Karimi K, Mojtabavi S, Tehrany PM, …, Nabavi N, et al. (2023). Chitosan-based nanoscale delivery systems in hepatocellular carcinoma: Versatile bio-platform with theranostic application. Int J Biol Macromol, 242(Pt 3), 124935. PubMed
57. Ebrahimi N, Far NP, Fakhr SS, …, Nabavi N, et al. (2023). The endocannabinoid system, a new gatekeeper in the pharmacology of human hepatocellular carcinoma. Environ Res, 228, 115914. PubMed
58. Almajidi YQ, Kadhim MM, Alsaikhan F, …, Nabavi N, et al. (2023). Doxorubicin-loaded micelles in tumor cell-specific chemotherapy. Environ Res, 227, 115722. PubMed
59. Hashemi M, Zandieh MA, Ziaolhagh S, …, Nabavi N, et al. (2023). Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective. Biochim Biophys Acta Mol Basis Dis, 1869(5), 166714. PubMed
60. Hashemi M, Sabouni E, Rahmanian P, …, Nabavi N, et al. (2023). Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance. Cell Mol Biol Lett, 28(1), 33. PubMed
61. Sabouni E, Nejad MM, Mojtabavi S, …, Nabavi N, et al. (2023). Unraveling the function of epithelial-mesenchymal transition (EMT) in colorectal cancer: Metastasis, therapy response, and revisiting molecular pathways. Biomed Pharmacother, 160, 114395. PubMed
62. Hashemi M, Zandieh MA, Talebi Y, …, Nabavi N, et al. (2023). Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies. Biomed Pharmacother, 160, 114392. PubMed
63. Hashemi M, Mirdamadi MSA, Talebi Y, …, Nabavi N, et al. (2023). Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents. Pharmacol Res, 187, 106568. PubMed
64. Hashemi M, Hasani S, Hajimazdarany S, …, Nabavi N, et al. (2022). Non-coding RNAs targeting notch signaling pathway in cancer: From proliferation to cancer therapy resistance. Int J Biol Macromol, 222(Pt A), 1151-1167. PubMed
65. Nann P, Nabavi N, Ziafat K, et al. (2022). Trends in opioid dispensing after common abdominal and orthopedic surgery procedures in British Columbia: a retrospective cohort analysis. Can J Anaesth, 69(8), 986-996. PubMed
66. Ziafat K, Polderman S, Nabavi N, et al. (2022). Opioid dispensing after Cesarean delivery in British Columbia: a historical cohort analysis from 2004 to 2019. Can J Anaesth, 69(8), 997-1006. PubMed
67. Mirzaei S, Paskeh MDA, Okina E, …, Nabavi N, et al. (2022). Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res, 41(1), 214. PubMed
68. Entezari M, Ghanbarirad M, Taheriazam A, …, Nabavi N, et al. (2022). Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling. Biomed Pharmacother, 150, 112963. PubMed
69. Madamsetty VS, Mohammadinejad R, Uzieliene I, …, Nabavi N, et al. (2022). Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems. ACS Biomater Sci Eng, 8(5), 1763-1790. PubMed
70. Mirzaei S, Gholami MH, Hushmandi K, …, Nabavi N, et al. (2022). Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol, 15(1), 50. PubMed
71. Ashrafizadeh M, Paskeh MDA, Mirzaei S, …, Nabavi N, et al. (2022). Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. J Exp Clin Cancer Res, 41(1), 105. PubMed
72. Mirzaei S, Gholami MH, Hushmandi K, …, Nabavi N, et al. (2022). The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol, 15(1), 18. PubMed
73. Ashrafizadeh M, Mirzaei S, Gholami MH, …, Nabavi N, et al. (2021). Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression. Carbohydr Polym, 272, 118491. PubMed
74. Ashrafizadeh M, Zarrabi A, Mirzaei S, …, Nabavi N, et al. (2021). Gallic acid for cancer therapy: Molecular mechanisms and boosting efficacy by nanoscopical delivery. Food Chem Toxicol, 157, 112576. PubMed
75. Oo HZ, Lohinai Z, Khazamipour N, …, Nabavi N, et al. (2021). Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer. Cancers (Basel), 13(17). PubMed
76. Ashrafizadeh M, Zarrabi A, Orouei S, …, Nabavi N, et al. (2021). Interplay between SOX9 transcription factor and microRNAs in cancer. Int J Biol Macromol, 183, 681-694. PubMed
77. Mather RL, Parolia A, Carson SE, …, Nabavi N, et al. (2021). The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms. Mol Oncol, 15(7), 1921-1941. PubMed
78. Ashrafizaveh S, Ashrafizadeh M, Zarrabi A, …, Nabavi N, et al. (2021). Long non-coding RNAs in the doxorubicin resistance of cancer cells. Cancer Lett, 508, 104-114. PubMed
79. Mirzaei S, Mohammadi AT, Gholami MH, …, Nabavi N, et al. (2021). Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance. Pharmacol Res, 167, 105575. PubMed
80. Mirzaei S, Gholami MH, Mahabady MK, …, Nabavi N, et al. (2021). Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation. Biomed Pharmacother, 133, 111077. PubMed
81. Ashrafizadeh M, Hushmandi K, Rahmani Moghadam E, …, Nabavi N, et al. (2020). Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer. Bioengineering (Basel), 7(3). PubMed
82. Shrestha R, Nabavi N, Volik S, et al. (2020). Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma. Cancers (Basel), 12(6). PubMed
83. Shrestha R, Nabavi N, Lin YY, et al. (2019). BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med, 11(1), 8. PubMed
84. Qu S, Xue H, Dong X, …, Nabavi N, et al. (2018). Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. Int J Cancer, 143(2), 419-429. PubMed
85. Nabavi N, Wei J, Lin D, Collins CC, Gout PW, Wang Y (2018). Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts. Front Genet, 9, 232. PubMed
86. Choi SYC, Ettinger SL, Lin D, …, Nabavi N, et al. (2018). Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. Cancer Med, 7(7), 3385-3392. PubMed
87. Ramnarine VR, Alshalalfa M, Mo F, …, Nabavi N, et al. (2018). The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience, 7(6). PubMed
88. Nabavi N, Saidy NRN, Venalainen E, et al. (2017). miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. Sci Rep, 7(1), 4079. PubMed
89. Lin D, Ettinger SL, Qu S, …, Nabavi N, et al. (2017). Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. Oncotarget, 8(16), 25928-25941. PubMed
90. Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, Mutti L (2016). Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. Genes Cancer, 7(11-12), 340-354. PubMed
91. Kim SM, Wang Y, Nabavi N, Liu Y, Correia MA (2016). Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame. Drug Metab Rev, 48(3), 405-33. PubMed
92. Shin J, He M, Liu Y, …, Nabavi N, et al. (2013). SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep, 5(3), 654-665. PubMed
93. Pustylnik S, Fiorino C, Nabavi N, et al. (2013). EB1 levels are elevated in ascorbic Acid (AA)-stimulated osteoblasts and mediate cell-cell adhesion-induced osteoblast differentiation. J Biol Chem, 288(30), 22096-110. PubMed
94. Durand M, Komarova SV, Bhargava A, …, Nabavi N, et al. (2013). Monocytes from patients with osteoarthritis display increased osteoclastogenesis and bone resorption: the In Vitro Osteoclast Differentiation in Arthritis study. Arthritis Rheum, 65(1), 148-58. PubMed
95. Nabavi N, Pustylnik S, Harrison RE (2012). Rab GTPase mediated procollagen trafficking in ascorbic acid stimulated osteoblasts. PLoS One, 7(9), e46265. PubMed
96. Nabavi N, Khandani A, Camirand A, Harrison RE (2011). Effects of microgravity on osteoclast bone resorption and osteoblast cytoskeletal organization and adhesion. Bone, 49(5), 965-74. PubMed
97. Hassanzadeh A, Nitsche M, Armstrong S, …, Nabavi N, et al. (2010). Optical waveguides formed by silver ion exchange in Schott SG11 glass for waveguide evanescent field fluorescence microscopy: evanescent images of HEK293 cells. J Biomed Opt, 15(3), 036018. PubMed
98. Nabavi N, Urukova Y, Cardelli M, Aubin JE, Harrison RE (2008). Lysosome dispersion in osteoblasts accommodates enhanced collagen production during differentiation. J Biol Chem, 283(28), 19678-90. PubMed

← Back to Publications